Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats

Sabine Strassburg, Stefan D. Anker, Tamara R. Castaneda, Lukas Burget, Diego Perez-Tilve, Paul T. Pfluger, Ruben Nogueiras, Heather Halem, Jesse Z. Dong, Michael D. Culler, Rakesh Datta, Matthias H. Tschöp

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), is the only circulating agent to powerfully promote a positive energy balance. Such action is mediated predominantly by central nervous system pathways controlling food intake, energy expenditure, and nutrient partitioning. The ghrelin pathway may therefore offer therapeutic potential for the treatment of catabolic states. However, the potency of the endogenous hormone ghrelin is limited due to a short half-life and the fragility of its bioactivity ensuring acylation at serine 3. Therefore, we tested the metabolic effects of two recently generated GHS-R agonists, BIM-28125 and BIM-28131, compared with ghrelin. All agents were administered continuously for 1 mo in doses of 50 and 500 nmol·kg-1·day-1 using implanted subcutaneous minipumps in rats. High-dose treatment with single agonists or ghrelin increased body weight gain by promoting fat mass, whereas BIM-28131 was the only one also increasing lean mass significantly. Food intake increased during treatment with BIM-28131 or ghrelin, whereas no effects on energy expenditure were detected. With the lower dose, only BIM-28131 had a significant effect on body weight. This also held true when the compound was administered by subcutaneous injection three times/day. No symptoms or signs of undesired effects were observed in any of the studies or treated groups. These results characterize BIM-28131 as a promising GHS-R agonist with an attractive action profile for the treatment of catabolic disease states such as cachexia.

Original languageEnglish
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume295
Issue number1
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Ghrelin Receptor
Ghrelin
Energy balance
Rats
Hormones
Energy Metabolism
Eating
Body Weight
Therapeutics
Acylation
Cachexia
Neurology
Subcutaneous Injections
Bioactivity
Serine
Nutrients
Signs and Symptoms
Weight Gain
Half-Life
Central Nervous System

Keywords

  • Body weight
  • Cachexia
  • Food intake

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Biochemistry

Cite this

Strassburg, S., Anker, S. D., Castaneda, T. R., Burget, L., Perez-Tilve, D., Pfluger, P. T., ... Tschöp, M. H. (2008). Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. American Journal of Physiology - Endocrinology and Metabolism, 295(1). https://doi.org/10.1152/ajpendo.00040.2008

Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. / Strassburg, Sabine; Anker, Stefan D.; Castaneda, Tamara R.; Burget, Lukas; Perez-Tilve, Diego; Pfluger, Paul T.; Nogueiras, Ruben; Halem, Heather; Dong, Jesse Z.; Culler, Michael D.; Datta, Rakesh; Tschöp, Matthias H.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 295, No. 1, 07.2008.

Research output: Contribution to journalArticle

Strassburg, S, Anker, SD, Castaneda, TR, Burget, L, Perez-Tilve, D, Pfluger, PT, Nogueiras, R, Halem, H, Dong, JZ, Culler, MD, Datta, R & Tschöp, MH 2008, 'Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats', American Journal of Physiology - Endocrinology and Metabolism, vol. 295, no. 1. https://doi.org/10.1152/ajpendo.00040.2008
Strassburg, Sabine ; Anker, Stefan D. ; Castaneda, Tamara R. ; Burget, Lukas ; Perez-Tilve, Diego ; Pfluger, Paul T. ; Nogueiras, Ruben ; Halem, Heather ; Dong, Jesse Z. ; Culler, Michael D. ; Datta, Rakesh ; Tschöp, Matthias H. / Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. In: American Journal of Physiology - Endocrinology and Metabolism. 2008 ; Vol. 295, No. 1.
@article{75fa46bdef8041128f6c7abc43dcd030,
title = "Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats",
abstract = "Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), is the only circulating agent to powerfully promote a positive energy balance. Such action is mediated predominantly by central nervous system pathways controlling food intake, energy expenditure, and nutrient partitioning. The ghrelin pathway may therefore offer therapeutic potential for the treatment of catabolic states. However, the potency of the endogenous hormone ghrelin is limited due to a short half-life and the fragility of its bioactivity ensuring acylation at serine 3. Therefore, we tested the metabolic effects of two recently generated GHS-R agonists, BIM-28125 and BIM-28131, compared with ghrelin. All agents were administered continuously for 1 mo in doses of 50 and 500 nmol·kg-1·day-1 using implanted subcutaneous minipumps in rats. High-dose treatment with single agonists or ghrelin increased body weight gain by promoting fat mass, whereas BIM-28131 was the only one also increasing lean mass significantly. Food intake increased during treatment with BIM-28131 or ghrelin, whereas no effects on energy expenditure were detected. With the lower dose, only BIM-28131 had a significant effect on body weight. This also held true when the compound was administered by subcutaneous injection three times/day. No symptoms or signs of undesired effects were observed in any of the studies or treated groups. These results characterize BIM-28131 as a promising GHS-R agonist with an attractive action profile for the treatment of catabolic disease states such as cachexia.",
keywords = "Body weight, Cachexia, Food intake",
author = "Sabine Strassburg and Anker, {Stefan D.} and Castaneda, {Tamara R.} and Lukas Burget and Diego Perez-Tilve and Pfluger, {Paul T.} and Ruben Nogueiras and Heather Halem and Dong, {Jesse Z.} and Culler, {Michael D.} and Rakesh Datta and Tsch{\"o}p, {Matthias H.}",
year = "2008",
month = "7",
doi = "10.1152/ajpendo.00040.2008",
language = "English",
volume = "295",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats

AU - Strassburg, Sabine

AU - Anker, Stefan D.

AU - Castaneda, Tamara R.

AU - Burget, Lukas

AU - Perez-Tilve, Diego

AU - Pfluger, Paul T.

AU - Nogueiras, Ruben

AU - Halem, Heather

AU - Dong, Jesse Z.

AU - Culler, Michael D.

AU - Datta, Rakesh

AU - Tschöp, Matthias H.

PY - 2008/7

Y1 - 2008/7

N2 - Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), is the only circulating agent to powerfully promote a positive energy balance. Such action is mediated predominantly by central nervous system pathways controlling food intake, energy expenditure, and nutrient partitioning. The ghrelin pathway may therefore offer therapeutic potential for the treatment of catabolic states. However, the potency of the endogenous hormone ghrelin is limited due to a short half-life and the fragility of its bioactivity ensuring acylation at serine 3. Therefore, we tested the metabolic effects of two recently generated GHS-R agonists, BIM-28125 and BIM-28131, compared with ghrelin. All agents were administered continuously for 1 mo in doses of 50 and 500 nmol·kg-1·day-1 using implanted subcutaneous minipumps in rats. High-dose treatment with single agonists or ghrelin increased body weight gain by promoting fat mass, whereas BIM-28131 was the only one also increasing lean mass significantly. Food intake increased during treatment with BIM-28131 or ghrelin, whereas no effects on energy expenditure were detected. With the lower dose, only BIM-28131 had a significant effect on body weight. This also held true when the compound was administered by subcutaneous injection three times/day. No symptoms or signs of undesired effects were observed in any of the studies or treated groups. These results characterize BIM-28131 as a promising GHS-R agonist with an attractive action profile for the treatment of catabolic disease states such as cachexia.

AB - Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), is the only circulating agent to powerfully promote a positive energy balance. Such action is mediated predominantly by central nervous system pathways controlling food intake, energy expenditure, and nutrient partitioning. The ghrelin pathway may therefore offer therapeutic potential for the treatment of catabolic states. However, the potency of the endogenous hormone ghrelin is limited due to a short half-life and the fragility of its bioactivity ensuring acylation at serine 3. Therefore, we tested the metabolic effects of two recently generated GHS-R agonists, BIM-28125 and BIM-28131, compared with ghrelin. All agents were administered continuously for 1 mo in doses of 50 and 500 nmol·kg-1·day-1 using implanted subcutaneous minipumps in rats. High-dose treatment with single agonists or ghrelin increased body weight gain by promoting fat mass, whereas BIM-28131 was the only one also increasing lean mass significantly. Food intake increased during treatment with BIM-28131 or ghrelin, whereas no effects on energy expenditure were detected. With the lower dose, only BIM-28131 had a significant effect on body weight. This also held true when the compound was administered by subcutaneous injection three times/day. No symptoms or signs of undesired effects were observed in any of the studies or treated groups. These results characterize BIM-28131 as a promising GHS-R agonist with an attractive action profile for the treatment of catabolic disease states such as cachexia.

KW - Body weight

KW - Cachexia

KW - Food intake

UR - http://www.scopus.com/inward/record.url?scp=50349090968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349090968&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00040.2008

DO - 10.1152/ajpendo.00040.2008

M3 - Article

VL - 295

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 1

ER -